Table 5 Completion rates for combined trial arms among regions a
Study program | Treatment group | North America | Western Europe | Australia/South Africa | Japan | Asia | Eastern Europe/Russia | South America/Mexico |
|---|---|---|---|---|---|---|---|---|
IDENTITY | Placebo | 291 (76.4)EE | 162 (81.4)EE | 37 (80.4) | 99 (90.0)EE | 79 (79.8) | 79 (59.4) | 70 (81.4) |
Semagacestat 140 mg PO | 198 (50.8) | 129 (60.9) | 29 (53.7) | 69 (64.5) | 58 (60.4) | 69 (48.9) | 31 (37.8) | |
EXPEDITION | Placebo | 325 (72.1) | 163 (76.5) | 32 (84.2) | 71 (87.7) | 59 (84.3) | 38 (61.3) | 82 (74.6) |
Solanezumab 400 mg IV | 303 (67.8)JP | 175 (80.7) | 35 (76.1) | 89 (89.0) | 57 (87.7) | 43 (75.4) | 74 (77.9) |